VCM
TNGX icon

Versant Capital Management’s Tango Therapeutics TNGX Stock Holding History

Versant Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28
Closed -$216 – 2428
2024
Q3 		$216 Buy
+28
New +$267 ﹤0.01% 1957

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Versant Capital Management's TNGX Position: Q4 2024 in Review

Versant Capital Management sold out of Tango Therapeutics (TNGX) in Q4 2024, closing a stake of 28 shares — an estimated $216 sold.

Versant Capital Management first reported a position in TNGX in Q3 2024 and held it in 1 quarter. The position peaked at $216 in Q3 2024. 137 funds tracked by Wall St. Rank hold TNGX as of Q4 2024.

  • Versant Capital Management reported no remaining Tango Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Versant Capital Management sold 28 Tango Therapeutics shares in Q4 2024, an estimated $216.
  • Versant Capital Management first reported a position in Tango Therapeutics in Q3 2024 and held it in 1 quarter.
  • Versant Capital Management's Tango Therapeutics position peaked at $216 in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2024.

Based on Versant Capital Management's 13F filing for Q4 2024, filed 3 Jan 2025.